A group of Italian biotech companies has recently entered the world race to contain and finally defeat the coronavirus, and are getting results. While the chronicles are full of Japanese miracle drugs and vaccine trials in the four corners of the world, Italian biotech is getting international recognition and is close to important trials.
“Perhaps more than other sectors, we are aware of what it means to face a pandemic,” said Riccardo Palmisano, president of Assobiotec-Federchimica, the trade association that brings together over 130 companies involved in biotechnology and pharmaceuticals (as well as agriculture and the environment). “For this reason, like the entire productive fabric, we have taken measures against the virus, we have done smart working and readjusted shifts, but the laboratories have never remained empty because at the end of our chain there is the patient, not only those affected by the coronavirus,” Palmisano continued.
For more information about the latest breakthrough in the biotech sector, install our companion app Born2invest. Read the most important financial headlines and be the first to find out when a vaccine against COVID-19 will be available.
Italian researchers are working hard to find a vaccine
Palmisano explained that there are several centers of excellence in the territory equipped to make a contribution against the virus, especially in two fields: diagnostics and vaccines.
In the field of testing, there is DiaSorin, a company based near Vercelli. With a very strong international presence, the company has developed a molecular diagnostic test capable of giving results on coronavirus positivity within an hour. The test is so sensitive that it is able to recognize the virus even in case of mutations.
The U.S. division of the company, DiaSorin Molecular, was one of the few companies to receive emergency approval from the U.S. Food and Drug Administration to proceed with the use of its tests, along with some federal funds. DiaSorin tests are carried out with machines that the company has already installed all over the world.
Irbm, ReiThera and Takis are among the companies that have entered the race to find a vaccine against COVID-19
Three Italian companies have also entered the vaccine race, and all three come from Lazio, where a pole of excellence has been created in recent years.
Irbm is a company that counts over 250 scientists and has entered in collaboration with the Jenner Institute of the University of Oxford to create a vaccine against the new coronavirus. Irbm has a lot of experience since back in 2016 the company developed a vaccine against Ebola. In addition, in recent years, Irbm has already done a lot of work on another parainfluenza virus, the adenovirus. Irbm has started the development of the first batch of vaccines for clinical trials (i.e. those on people), which hopes to start before the summer.
ReiThera was also involved in the development of a vaccine to stop Ebola. The company’s vaccine against the coronavirus is currently being tested in vitro and on animals. The company should have a 10,000-dose batch ready to begin clinical trials by the end of May.
Similar timing for Takis, a biotech company that has developed four possible variants of the vaccine. The company started animal testing in collaboration with the Spallanzani Institute. The first results should arrive by the end of April, and clinical trials will take place by the end of the year.
“Italy has many scientists of international excellence and we should not need a global pandemic to remind us of that,” said Palmisano. “We have the weapons to fight this emergency and defeat it, but there are ways to be better prepared when the next one comes.”
Palmisano recalled that research funding is not yet at the European level: “The target for 2020 would have been to allocate 3% of GDP to research, but we are still at 1.3. And this is why when this crisis is over we need a national plan: Italy has all the capacity to be a protagonist.”
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in IL FOGLIO, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The coronavirus resurgence keeps demand on the futures market at low levels
Coffee futures were higher and were led higher by New York as it caught up to the recent strength in...
The Government of Catalonia awards Roche a €9.2 million contract for analysis services
The Swiss pharmaceutical company Roche will supply reagents and consumables and will provide the necessary equipment to carry out analytical...
PR Tech: How investments in the media market changed?
The pandemic has affected all sectors of the economy, including the advertising market. According to Business Insider, despite the hit...
The crypto market is on the rise, while the U.S. GDP suffers the biggest slump in its history
The economic turmoil caused by the coronavirus pandemic has thrown the U.S. GDP in the second quarter of the year...
Three equity crowdfunding campaigns in Italy end with deposits of over €1 million
AorticLab closed the equity crowdfunding campaign on the Doorway platform with a collection of $1.54 million (€1.3 million). PMI TOP...
Cannabis7 days ago
A French company will produce fuels from hemp
Crypto6 days ago
Ethereum course increases by 36% and DeFi breaks the $4 billion mark
Featured4 days ago
Supply@Me Capital ready to close the first securitization of the overall €970 million program
Featured7 days ago
Princes Industrie Alimentari enhances the Apulian tomato supply chain